U.S. FDA grants Breakthrough Therapy Designation for Roche's investigational medicine ocrelizumab in primary progressive multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for the investigational medicine ocrelizumab (OCREVUSTM) for the treatment of people with primary progressive multiple sclerosis (PPMS).
Bristol-Myers Squibb and Dana-Farber Cancer Institute enter into a collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Dana-Farber Cancer Institute today announced that they have entered into a research collaboration agreement as part of the Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.
UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration
- Details
- Category: UCB
UCB and Baylor College of Medicine announced that they have started a strategic research alliance, led at Baylor by Professor Huda Zoghbi, that aims to discover new therapeutics to treat neurodegenerative disease.
Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
- Details
- Category: Novartis
Sandoz, a Novartis company and the global leader in biosimilars, announced today that the European Medicines Agency (EMA) has accepted their Marketing Authorization Application (MAA) for its biosimilar to Amgen's EU-licensed Neulasta®* (pegfilgrastim) - a long-acting recombinant human granulocyte colony-stimulating factor (G-CSF).
Bayer continues to grow its open innovation activities
- Details
- Category: Bayer
With Grants4Indications™ Bayer has launched its fifth global crowdsourcing initiative. This latest web-based grant program promotes the exploration of new indications with the aim to discover novel potential therapeutic areas for Bayer compounds.
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced the executive leadership team for the combined Pfizer and Allergan plc (NYSE: AGN) business following the close of the proposed transaction.
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical development in the U.S. and Europe, is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).
More Pharma News ...
- Bristol-Myers Squibb Foundation awards eight grants totaling nearly $11.5M to make lung and skin cancer screening
- Abbott to Acquire Alere, becoming leader in point of care testing
- Merck announces new biopharma heads for North America and China
- European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable
- Merck launches Vivera in Latin America
- Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia
- Sanofi Pasteur provides key support to the Human Vaccines Project